C12N 2760/10062
By genetic engineering
Official title: by genetic engineering
C12N2760/10062 (By genetic engineering) appears on 4 US grants and 9 published applications in this corpus.
Search patents in C12N- Granted patents
- 4
- Published applications
- 9
- Assignees
- 5
- Inventors
- 28
- Latest grant
- 2 May 2023
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2016 | 0 | 1 |
| 2017 | 0 | 1 |
| 2018 | 1 | 1 |
| 2019 | 0 | 0 |
| 2020 | 2 | 0 |
| 2021 | 0 | 2 |
| 2022 | 0 | 0 |
| 2023 | 1 | 0 |
| 2024 | 0 | 1 |
| 2025 | 0 | 3 |
By publication year.
Recent patents
- Immunogenic composition comprising a recombinant attenuated mopeia virus with a modified nucleoprotein displaying reduced exonuclease activity2 May 2023US 11,638,751 B2Institut Pasteur
- Recombinant attenuated Mopeia virus comprising a modified nucleoprotein with reduced exonuclease activity1 Dec 2020US 10,849,969 B2Institut Pasteur
- Tri-segmented arenaviruses as vaccine vectors28 Jul 2020US 10,722,564 B2Universite De Geneve
- Methods and compositions related to reorganization of arenavirus genome for development of novel arenavirus live-attenuated vaccines (LAV)17 Apr 2018US 9,943,585 B2University of Rochester
- Multivalent mopevac-based immunogenic composition for vaccination against new world arenaviruses and therapeutic use(s) thereof3 Jul 2025US 2025/0213670 A1
- Live attenuated junin virus and related compositions and methods3 Jul 2025US 2025/0213672 A1Utah State University
- Modified arenavirus particles expressing mutant kras, mutated cancer driver gene, or tumor-associated antigen as cancer immunotherapies6 Mar 2025US 2025/0073324 A1Hookipa Biotech GmbH
- Tri-segmented arenaviruses as vaccine vectors14 Mar 2024US 2024/0082376 A1Universite De Geneve
- Recombinant mopeia virus and vaccine platform8 Jul 2021US 2021/0205436 A1Institut Pasteur
Most cited
By later US patents